Emergex CEO and ex-research director at the University of Oxford, Thomas Rademacher, spoke with Scrip about the myth of the “Wuhan virus” and why synthetic T-cell adaptive vaccines are expected to be superior to RNA/mRNA ones. More partners are being sought for additional delivery mechanisms, the founder of the UK-based, clinical-stage biotech says in this podcast interview.
Podcast Interview With Emergex Vaccines CEO, Thomas Rademacher
The pandemic renewed interest in vaccines, and with Pfizer Inc. and Moderna, Inc. making mRNA vaccines a reality, and a hugely commercially successful one at that, more vaccine companies are in the limelight.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
